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Professional recommendations for the return of results from exome and whole-genome sequencing (ES/WGS) have been controversial.
The lack of clear guidance about whether and, if so, how to return ES/WGS incidental results limits the extent to which individuals and
families might benefit from ES/WGS. The perspectives of genetics professionals, particularly those at the forefront of using ES/WGS in
clinics, are largely unknown. Data on stakeholder perspectives could help clarify how to weigh expert positions and recommendations.
We conducted an online survey of 9,857 genetics professionals to learn their attitudes on the return of incidental results from ES/WGS
and the recent American College of Medical Genetic and Genomics Recommendations for Reporting of Incidental Findings in Clinical
Exome and Genome Sequencing. Of the 847 respondents, 760 completed the survey. The overwhelming majority of respondents
thought that incidental ES/WGS results should be offered to adult patients (85%), healthy adults (75%), and the parents of a child
with a medical condition (74%). The majority thought that incidental results about adult-onset conditions (62%) and carrier status
(62%) should be offered to the parents of a child with a medical condition. About half thought that offered results should not be limited
to those deemed clinically actionable. The vast majority (81%) thought that individual preferences should guide return. Genetics
professionals’ perspectives on the return of ES/WGS results differed substantially from current recommendations, underscoring the
need to establish clear purpose for recommendations on the return of incidental ES/WGS results as professional societies grapple
with developing and updating recommendations.Introduction
The unprecedented clinical diagnostic power of exome and
whole-genome sequencing (ES/WGS) has motivated rapid
commercialization of ES/WGS for research and clinical ser-
vice. Because ES/WGS can assess virtually every gene in the
human genome for disease-predisposing variants, it can
provide information on putatively every allele that influ-
ences risk of disease. Accordingly, even if no primary result
(i.e., the reason for which the test was ordered) is found via
ES/WGS, there are multiple, and potentially hundreds, of
so-called secondary or incidental results that can be offered
for return to individuals and families.1,2 Whether to return
all or some of these incidental results and, if in part, which
incidental results to return, how to most effectively return
them, and how best to use incidental results to improve
health is unclear but has dominated professional discourse
about the potential benefits and risks of using ES/WGS.3–5
The lack of an informed approach for returning incidental
results from ES/WGS is compounded by existing chal-
lenges to the traditional process of communicating and
disseminating genetic results.
The lack of clear guidance about whether and, if so, how
to return incidental results from ES/WGS limits the extent
to which individuals and families are empowered to trans-
late genomic information into improved lifestyles, medical
care, and ultimately long-term health. Recently, the Amer-
ican College of Medical Genetics and Genomics (ACMG)
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Thsults from ES/WGS.6,7 These recommendations have
proven to be highly controversial; a relatively small but
outspoken group of researchers and ethicists are expressing
widely divergent views on (1) whether and, if so, what inci-
dental results should be offered for return, (2) issues of
informed consent, and (3) providing results for adult-onset
conditions to the parents of children who undergo ES/
WGS.8–14 Despite the debate, the perspectives of genetics
professionals, particularly those at the forefront of using
ES/WGS in clinical settings (i.e., medical geneticists and
genetic counselors), on the return of incidental results
from ES/WGS or the ACMG recommendations are largely
unknown. Empirical data on such stakeholder perspectives
could help clarify how to weigh various expert positions
and recommendations. To this end, we developed a web-
based survey and queried nearly 10,000 genetics profes-
sionals about the return of incidental results from ES/WGS.Subjects and Methods
We sought to characterize genetics professionals’ attitudes toward
(1) the return of clinical ES/WGS results (12 items), (2) the process
of returning results (five items), and (3) the ACMG recommenda-
tions for reporting incidental findings from clinical ES/WGS
(nine items). Personal and professional demographics were also
collected (nine items). A five-point Likert-type scale was used to
rate the level of agreement in the majority of items assessing atti-
tudes. Six items utilized dichotomous responses (‘‘yes’’ or ‘‘no’’)
and a ‘‘don’t know’’ option. Six items used pregiven categorical; 2Treuman Katz Center for Pediatric Bioethics, Seattle Children’s Research
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response options without restriction (e.g., indicate all that apply).
Each page of items included a space for comments. A complete list
of survey questions is included in Table S1, available online.
We developed survey items from a review of the medical litera-
ture, including previously published surveys on the return of
genetic results and interviews with genetics professionals on the
return of results, to identify key topics and examples. We pro-
grammed a draft of a 35-item survey with SurveyMonkey. This
draft survey was pilot tested with five individuals who are medical
geneticists, genetic counselors, and or other genetics profes-
sionals. After editing survey items per their feedback, we tested
the survey again on ten individuals to identify typographical er-
rors, problems in question logic, and instructions that needed
further clarification.
To identify potential respondents, we collected e-mail addresses,
professional degrees, and states of residence from the publically
available web-based directories of three different societies of ge-
netics professionals: the American Society of Human Genetics
(ASHG), the ACMG, and the National Society of Genetic Coun-
selors (NSGC). Although nongenetics health professionals may
order ES/WGS, we chose to focus our questions on genetics profes-
sionals because collectively they are at the forefront of developing
and utilizing clinical ES/WGS in clinical settings. Available contact
information was collected in the fall of 2012 and was combined to
form a single nonredundant e-mail distribution list. Individuals
without an e-mail address were excluded. The University of Wash-
ington Human Subjects Division reviewed the study protocol and
determined it to be nonhuman subjects research because respon-
dents were anonymous.
On August 19, 2013, an e-mail was sent to 9,857 addresses
to invite genetics professionals to complete the online survey. Thir-
ty invitations were returned automatically as a result of invalid
addresses. About half (~50%) of survey responses were received
within the first 24 hours. Two reminders to respond to the survey
were sent by e-mail over the next 4 weeks. The survey was made
accessible in SurveyMonkey until September 17, 2013.
The survey provided a brief introduction explaining its purpose;
definitions of relevant terms, such as ‘‘actionable result,’’ ‘‘primary
result,’’ and ‘‘incidental finding’’; and the following description of
the ACMG recommendations: ‘‘In March 2013, the ACMG
released their recommendations for reporting of incidental find-
ings in clinical exome and genome sequencing. They recommen-
ded that laboratories performing clinical sequencing seek and
report mutations known or expected to be pathogenic in 56 genes
(i.e., the minimum list) in all patients, irrespective of age, who un-
dergo germline (or constitutional) exome/genome sequencing.’’
Also includedwas a direct electronic link to the ACMG recommen-
dations as a reference for respondents.
Survey response datawere downloaded from SurveyMonkey and
analyzed with Stata/IC (Intercooled Stata) version 12. We used
descriptive statistics to summarize responses to each survey item.
To facilitate analysis and interpretation, we collapsed response cat-
egories for Likert-scale-type items to construct an ‘‘agree’’ category
combining both ‘‘strongly agree’’ and ‘‘agree’’ and a corresponding
‘‘disagree’’ category. ‘‘Neither agree nor disagree’’ responses were
tabulated. Because respondents were permitted to skip items, the
sample size varied by item.
To assess response bias, we compared our respondents’ demo-
graphic data to data available on nonrespondents from our initial
e-mail invitation list and to reported estimates of demographic
characteristics from studies conducted among the membership
of the NSGC,15medical geneticists certified by the American Board78 The American Journal of Human Genetics 95, 77–84, July 3, 2014of Medical Genetics (ABMG),16 and ASHG members.17 Additional
data on common demographic variables among members of
ASHG and ACMGwere unavailable. We used chi-square (c2) good-
ness-of-fit tests to evaluate categorical demographic variables and
evaluatedmean age by a two-sample t test with unequal variances.Results
The survey response rate was 9% (n ¼ 847/9,857), and the
majority of respondents finished the survey so that the
overall completion rate was 8% (n ¼ 760/9,857). The ma-
jority of respondents were female (58%), white (89.8%),
and of non-Hispanic ethnicity (96%) and resided in the
United States (81%) (Table S2). The mean age of respon-
dents was 46.2 years and ranged from 23 to 85 years.
Ninety-nine percent of respondents had a master’s degree,
Ph.D., medical degree, or a combination of Ph.D. andmed-
ical degree. Several professions, including clinical geneti-
cist (24%) genetic counselor (22%), and human geneticist
(19%), were well represented among respondents. Three
quarters of respondents, including those in clinical ge-
netics research (79%), basic science research (67%), patient
care (64%) and Ethical, Legal, and Social Implications
(ELSI) research (49%), were engaged in multiple types
of work. The majority of respondents (73%) worked in
academia.
Comparison to other sources of demographic data for ge-
netics professionals suggested that nonresponse was not a
substantial source of bias (Table S3). Self-identified genetic
counselors who responded did not differ significantly in
gender, age, race, or education from those who responded
to the NSGC’s 2012 professional survey.15 The only as-
sessed variable that differed was work environment (c2 ¼
68.04, 3 degrees of freedom [df], p ¼ 1.1 3 1014); specif-
ically, the proportion of academics was greater in the
survey respondents than in the overall field of genetic
counselors. Self-identified medical geneticists (including
clinical geneticists) who responded did not differ signifi-
cantly in gender, age, education, or work environment
from those reported in a 2003 ABMG workforce survey.16
A comparison of age, education, and work environment
between survey respondents and results from a 1989
ASHGmember survey produced mixed results.17 Although
no difference was observed in work environment, the
distribution of age (two-sample t test unequal variance
t ¼ 8.5318, p < 0.0001) and education (c2 ¼ 44.38, 3 df,
p¼ 1.33 109) differed significantly. As might be expected
from such a heterogeneous sample of genetics profes-
sionals and a gap of nearly a quarter century, the trend
was for a higher proportion of younger professionals and
individuals with either a master’s of science or a doctorate
in both medicine (i.e., M.D.) and philosophy (i.e., Ph.D.)
in our survey. Finally, a comparison of educational degrees
and geographical locations (i.e., the Northeast, Midwest,
South, and West) between survey respondents and nonre-
spondents revealed no significant differences in education
or geographic region (Table S3).
Overall Attitudes toward the Return of Incidental
Results from Clinical ES/WGS
The overwhelming majority of genetics professionals
(85%, n ¼ 648/763) agreed that incidental results from
ES/WGS should be offered to adult patients, and three-
quarters of professionals agreed that incidental ES/WGS
results should be offered to healthy adults (75%, n ¼
567/760) and the parents of a child with a medical condi-
tion (74%, n ¼ 562/762). Genetics professionals were split
almost evenly as to whether only actionable results from
ES/WGS should be offered for return to adult patients, par-
ents of a child with a medical condition, or healthy adults
(Figure 1A). Almost all respondents (88%, n ¼ 665/755)
thought that results about childhood-onset conditions
should be offered to the parents of a child who has a med-
ical condition and who has undergone clinical ES/WGS.
The majority of respondents also agreed with offering par-
ents their child’s results for adult-onset conditions (62%,
n ¼ 467/753) and carrier status (62%, n ¼ 471/757).
The vast majority of genetics professionals (81%, n ¼
673/836) agreed that the preferences of a patient or family
should guide which incidental results are offered for re-
turn. The majority of professionals (78%, n ¼ 593/757)
thought that patients should be able to choose which inci-
dental results to receive after a healthcare provider has
decided which results should be offered for return, even
though less than half of respondents (44%, n ¼ 330/757)
thought that giving patients and families the option to
choose which results to receive would improve care. Twice
as many respondents (58%, n ¼ 442/759 versus 29%, n ¼
219/759) thought it not ‘‘too difficult to allow patient/fam-
ily preferences to inform a healthcare provider which inci-
dental findings from ES/WGS should be offered for return.’’
To this end, the majority of genetics professionals (66%,
n ¼ 503/759) thought that a web-based tool could facil-
itate assessment of patient preferences for the return of
incidental findings.
Genetics professionals were asked to complete the state-
ment ‘‘Healthcare providers have an obligation to offer re-
turn of positive incidental findings from clinical ES/WGS
to patients for [different types of conditions]’’ (Figure S1).
Respondents could choose more than one response cate-
gory. The majority completed the statement with results
about Mendelian conditions (67%, n ¼ 535/794) and re-
sults that inform the potential for adverse drug reactions
(i.e., pharmacogenomic) (61%, n ¼ 488/794). Nearly half
(49%, n ¼ 393/794) thought results about carrier status
should be offered for return. Only one-fifth (20%, n ¼
156/794) thought there was an obligation to offer inci-
dental results for complex traits. Twenty-five percent
(n ¼ 196/794) of respondents indicated that healthcare
providers had no obligation to offer incidental results.
A total of 349 respondents provided information about
ES/WGS results that they ‘‘typically’’ return (Figure S1).
Ninety-four percent (n ¼ 328/349) offer a primary result.
Sixty-eight percent (n ¼ 239/349) offer incidental results
for Mendelian conditions. Nearly half offer incidental re-Thsults for adverse drug response (47%, n¼ 164/349) and car-
rier status (45%, n ¼ 157/349). Only twenty-five percent
(n ¼ 69/349) offer incidental results for complex condi-
tions. Review of qualitative comments from respondents
who indicated that they do not typically offer a primary
result (Table S4) revealed that most of these individuals
answered incorrectly and had never returned ES/WGS
results in a clinical setting. Excluding these responses,
virtually all respondents who conduct clinical ES/WGS
offer primary results.
Attitudes about How to Offer Incidental Results for
Return
Genetics professionals most frequently (79%, n ¼ 593/
755) ranked a ‘‘face-to-face meeting with a genetic coun-
selor’’ as the preferred approach to returning an incidental
result (Table 1). Alternatives that also ranked high included
return via a ‘‘phone call with a genetic counselor’’ (63%,
n ¼ 476/755) and via ‘‘an interactive website with access
to a genetic counselor by phone or online’’ (53%, n ¼
403/755). Fifty-four percent (n ¼ 409/756) of respondents
thought that ‘‘an online or web-based tool could facilitate
return of incidental findings from ES/WGS.’’ The least
preferred (81%, n ¼ 610/755), or the last-ranked approach
to returning incidental results, was notification via con-
ventional mail. Consistent with these responses, most ge-
netics professionals thought that incidental results from
ES/WGS could not be communicated effectively by con-
ventional mail (61%, n ¼ 458/753) or e-mail (57%, n ¼
431/751), although 44% (n ¼ 329/749) of respondents
thought that a web-based tool could be used effectively
to communicate ES/WGS results (Figure 1B).
Attitudes toward the ACMG Recommendations on
Incidental Results from ES/WGS
The majority of genetics professionals (68%, n ¼ 573/840)
agreed that results identified from the ACMG minimum
list of genes should be reported regardless of the indication
for sequencing (Figure 1C). The majority (57%, n ¼ 482/
840) disagreed that healthcare providers should decide
which of these results should be returned. Genetics profes-
sionals were asked how they would respond to the situa-
tion where patients or families decline to receive incidental
results from the ACMG minimum list (Figure S1). The ma-
jority of respondents (58%, n ¼ 464/795) indicated that
they would perform ES/WGS and not return incidental re-
sults per the request of the patient or family. Nearly half
(47%, n ¼ 376/795) would discuss each possible incidental
result with the patient or family and offer for return only
the results they opted to receive. Twenty-two percent
(n¼ 175/795) would not perform ES/WGS if an alternative
but less desirable test were available. Only 6% (n¼ 48/795)
of respondents would decline to perform ES/WGS if no
alternative test were available.
The majority of genetics professionals (65%, n ¼ 518/
799) thought that the biggest challenge in returning
incidental results from ES/WGS is that most healthcaree American Journal of Human Genetics 95, 77–84, July 3, 2014 79
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Figure 1. Attitudes of Genetics Professionals toward the Return of Incidental Results
This figure illustrates genetics professionals’ (A) overall attitudes toward the return of incidental results from clinical ES/WGS, (B) atti-
tudes about how to offer incidental results for return, and (C) attitudes toward the ACMG recommendations on incidental results from
ES/WGS. Question number (e.g., 1) corresponds to the original question number on the online survey. Sample size (n) is presented and
varies per question because respondents were allowed to skip questions. Blue bars indicate the proportion of respondents who agreed
(including both ‘‘strongly agree’’ and ‘‘agree’’) with corresponding statements or answered ‘‘yes’’ to corresponding questions. Orange
bars indicate the proportion of respondents who disagreed (including both ‘‘strongly disagree’’ and ‘‘disagree’’) with corresponding
(legend continued on next page)
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Table 1. Attitudes toward the Mode of Return in Response to Question 22a
First Choice Second Choice Third Choice Last Choice
A report sent in the mail 2.3% (17) 4.0% (30) 13.0% (98) 80.8% (610)
A phone call with a genetic counselor 5.6% (42) 63.0% (476) 26.5% (200) 4.9% (37)
An interactive website with access to a genetic counselor by phone or online 13.6% (103) 23.4% (177) 53.4% (403) 9.5% (72)
A face-to-face meeting with a genetic counselor 78.5% (593) 9.5% (72) 7.2% (54) 4.8% (36)
Italics indicate the largest proportion of responses per rank order.
aQuestion 22: Rank the following responses to the statement in order of preference: ‘‘I think incidental findings should be communicated by .’’ (n ¼ 755).providers do not have the time and/or expertise to return
incidental findings (Figure S1). Approximately half of
genetics professionals considered it a challenge to not
allow patients or families to select which incidental results
they want to receive on the basis of their values (52%, n ¼
413/799) or to opt out of receiving incidental results (49%,
n ¼ 389/799). One of every two genetics professionals
(48%, n ¼ 386/799) thought returning incidental results
from ES/WGS for adult-onset conditions to patients who
are minors would be a major challenge. Only 23% (n ¼
185/799) thought identifying incidental results in ES/
WGS data would be burdensome for a service lab, and
one in five thought returning incidental ES/WGS results
would increase the cost of healthcare.
We also asked respondents about possible concerns they
might have for individuals to whom incidental results
from ES/WGS were offered per the ACMG recommenda-
tions (Figure S1). Given the options provided, the over-
whelming majority of genetics professionals were con-
cerned that an individual might experience stress and
anxiety (74%, n ¼ 591/797). Only one-third were con-
cerned that individuals might experience discrimination
(31%, n ¼ 247/797) or that their privacy would be violated
(26%, n ¼ 210/797). Only 14% (n ¼ 113/797) of genetics
professionals had no concerns.Discussion
Several major conclusions about the attitudes of genetics
professionals toward the return of incidental results from
ES/WGS can be drawn from our findings. First, the over-
whelming majority of respondents think that incidental
results from ES/WGS should be offered to adult patients,
healthy adults, and parents of a child with a medical con-
dition. Second, although somewhat divided, the majoritystatements or answered ‘‘no’’ to corresponding questions. Grey bars i
nor disagree’’ for corresponding statements or answered ‘‘don’t know
ages calculated with the total number of respondents for each corre
small SEs ranged between 1% and 2%, bars are not shown. Colored
or disagreed (orange) by grouped categories of self-reported professio
icist, and genetic counselor), researcher (n ¼ 207, including human
ELSI researcher (n ¼ 26). A two-sample test of proportion was used
between clinicians and researchers. One asterisk indicates a significa
icant difference with a p value < 0.01.
Ththink that incidental results about adult-onset conditions
and carrier status should be offered to the parents of a child
who has a medical condition and who has undergone ES/
WGS. Third, about half think that results offered for return
should not be limited to those deemed clinically action-
able. Finally, the vast majority think that the return of inci-
dental results should be guided by individual preferences.
Although comparisons to other professional surveys
and our overall survey distribution list suggest demo-
graphic and professional similarities between respondents
and nonrespondents, greater confidence in the generaliz-
ability of our results would be afforded by a study of
nonrespondents.
General consensus among experts is that incidental re-
sults of clinical utility should be offered for return but
that healthcare providers should proceed cautiously with
disclosing results by accounting for the context of the
encounter.3,18–21 Our survey results indicate that genetics
professionals across a broad range of provider roles (e.g.,
medical geneticists and genetic counselors) overwhelm-
ingly agree that incidental results from ES/WGS should
be offered for return. However, genetics professionals
express considerable openness toward the acceptable con-
texts in which results should be offered. Specifically, a ma-
jority of genetics professionals agreed with offering parents
their child’s results for adult-onset conditions and carrier
status, and nearly half of genetics professionals who return
results from clinical ES/WGS ‘‘typically return’’ incidental
results for adverse drug reactions and carrier status. These
perspectives are consistent with the need for ‘‘flexibility’’
in policies governing the return of results22 and the need
for further consideration of what types of results, beyond
the ‘‘minimum floor,’’ should be offered for return.
Nearly half of survey respondents disagreed that only
actionable results should be offered for return of incidental
ES/WGS results. The importance of medical or clinicalndicate the proportion of respondents who selected ‘‘neither agree
’’ to corresponding questions. All bar values are rounded percent-
sponding statement or question (n) as the denominator. Because
circles indicate the proportion of respondents who agreed (blue)
n: clinician (n ¼ 380, including clinical geneticist, medical genet-
geneticist, population geneticist, and genetic epidemiologist), and
for assessing significant differences in agreement or disagreement
nt difference with a p value < 0.05; two asterisks indicate a signif-
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actionability as a criterion for return has been widely
debated.14,23–27 At face value, actionability is a convincing
reason for offering incidental results, yet defining what is
actionable has proven to be challenging.28,29 Furthermore,
evidence that actionability is the most important consider-
ation among clinical genetics professionals has been
inconsistent, perhaps in part because they have not been
asked about the value of personal utility for their pa-
tients.19,24 Debate about individual preferences for results
has focused on whether preferences should be considered
in the return of results and is most often polarized around
the individual’s right to refuse or opt out of receiving re-
sults.10,14,30,31 We provide clear evidence that genetics pro-
fessionals value individuals’ and families’ preferences and
that their preferences should guide the offer of incidental
ES/WGS results.
Despite the substantial attention paid to the return of
incidental ES/WGS results, little has been given to the
best approaches for operationalizing the return of results.
As we have articulated elsewhere, we think that conven-
tional approaches to returning genetic results is far from
optimal for the volume of incidental results expected
from clinical ES/WGS.32,33 Our finding that genetics pro-
fessionals consider lack of time and expertise as the most
important practical challenge confirms the need for new
tools to efficiently manage, if not transform, the return-
of-results process for individuals and families.32 Accord-
ingly, the openness of genetics professionals to different
modes of returning incidental ES/WGS results provides
an opportunity to consider innovative approaches to re-
turning genetic and/or genomic results, in general, and
incidental ES/WGS results in particular.34
Overall, our results suggest that many of the views of ge-
netics professionals differ from those of the experts who
developed the ACMG recommendations for the return of
incidental ES/WGS results. It is likely that genetics profes-
sionals and experts agree on many of the issues and chal-
lenges in offering and returning incidental ES/WGS results
but disagree on the relative weight each issue should be
afforded in policy and practice. For instance, genetics pro-
fessionals appeared to place greater weight on the value of
offering results that might be of utility (e.g., carrier status
and adult-onset conditions), but not necessarily action-
able, suggesting that they recognize the potential benefits
such results might have over an extended period of time.
Genetics professionals also placed greater weight on sup-
porting the right of individuals to selectively choose
among results offered for return and to oppose disclosure
altogether. Collectively, these trends suggest that genetics
professionals prioritize flexibility in what incidental ES/
WGS results should be offered for return and take a broader
view of how to incorporate individual and family prefer-
ences about what results should be offered for return. In
turn, this allows individuals and families the opportunity
to fine tune, in partnership with their healthcare provider,
the balance between maximizing benefits and minimizing
potential harms.82 The American Journal of Human Genetics 95, 77–84, July 3, 2014Creating recommendations without consensus of the
membership can result in a need for reconsideration and
rapid modification. Since the release of the ACMG recom-
mendations in March 2013,4 genetics professionals have
broadly expressed concern and dissatisfaction with several
major provisions. Perhaps in response to these criticisms,
at least in part, the ACMG has issued one memo of clarifi-
cation8 and one press release alluding to a modification
allowing for an ‘‘opt-out’’ provision.35 Indeed, the impor-
tance of including an ‘‘opt-out’’ provision to the ACMG
recommendations is evidenced by the 22% of respondents
who might order a less useful test in lieu of ES/WGS if an
individual elected not to receive incidental results. How-
ever, our results suggest that the gap between these modi-
fied recommendations on the return of incidental ES/WGS
results and the views and practices of genetics profes-
sionals continues to be substantial.
Our findings raise themore general question as towhat is
the purpose of recommendations from a professional body
such as the ACMG. Specifically, are recommendations in-
tended to identify and standardize desirable practices across
a profession or intended to reflect a general consensus
amongpractitionerswithin afield suchasmedical genetics?
Both have precedence within and beyond the field of med-
ical genetics, but most examples (e.g., childhood vaccina-
tions) are founded on a greater degree of certainty about
the benefits and associated costs (e.g., false positives) of
such policies. Given that the benefits of the return of inci-
dental ES/WGS results per the ACMG recommendations
are largely unknown, and are the focus of many studies
currently underway, such a functional view of expert-
driven policymaking seems premature.36 Likewise, in the
presence of so many mixed perspectives about the return
of incidental ES/WGS results, theACMGrecommendations
clearly cannot reflect a general consensus. Either way, our
survey results and the questions they raise underscore the
need to establish a clear purpose for recommendations on
the return of incidental ES/WGS results as other profes-
sional societies grapple with whether to consider devel-
oping recommendations or guidelines of their own.Supplemental Data
Supplemental Data include one figure and four tables and can be
found with this article online at http://dx.doi.org/10.1016/j.
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